Wootton R, Hammond B J
Br J Radiol. 1978 Apr;51(604):265-72. doi: 10.1259/0007-1285-51-604-265.
The administration of iodide for thyroid blocking is now known to carry its own risks, at least in certain categories of patients. We have therefore made a theoretical study by computer simulation of the efficacy of various thyroid blocking regimes. In the case of injected 125I- or 131I-iodide, substantial thyroid protection may theoretically be achieved by a single oral dose of inorganic iodide, for example a 90% reduction in radiation dose is produced by only 20 mg iodide. Repeating the initial blocking dose is of little value. A single blocking dose, however, affords poor protection against radioiodine released from labelled plasma proteins. Both for short-lived proteins such as fibrinogen, and for the longer-lived proteins such as albumin, the optimum dosage schedule appears to be stable iodide given daily for two to three weeks. For instance, 10 mg daily for a fortnight will reduce thyroid irradiation by a factor of ten following injection of 125I-fibrinogen.
现在已知,至少在某些类型的患者中,使用碘化物进行甲状腺阻滞本身也存在风险。因此,我们通过计算机模拟对各种甲状腺阻滞方案的效果进行了理论研究。对于注射的125I-或131I-碘化物,理论上单次口服无机碘化物可实现对甲状腺的实质性保护,例如仅20mg碘化物就能使辐射剂量降低90%。重复初始阻滞剂量几乎没有价值。然而,单次阻滞剂量对标记血浆蛋白释放的放射性碘的防护效果不佳。对于诸如纤维蛋白原等短寿命蛋白以及诸如白蛋白等长寿命蛋白,最佳给药方案似乎是连续两到三周每天给予稳定碘化物。例如,注射125I-纤维蛋白原后,连续两周每天服用10mg碘化物可使甲状腺辐射降低至十分之一。